Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Information for Infusion Sites

COVID-19 Monoclonal Antibody Therapeutics: Allocation and Distribution

HHS/ASPR has purchased supplies of two monoclonal antibody therapeutics, casirivimab/imdevimab and bamlanivimab, and we are committed to the equitable and efficient distribution of these treatments with the goal of reaching as many patients as possible, no matter where in the country they live and regardless of their income.

HHS  has supported the development of these products and is working with our partners to allocate the product  to states, territories, and federal entities to help reduce the need for hospitalization in high-risk patients.  We are working to get these products to long-term care facilities, dialysis centers, federally qualified health centers and correctional facilities through the SPEED program.  HHS has also established a treatment locator to help patients find local treatment options.

 

mAb icon

SPEED

The SPEED (Special Projects for Equitable and Efficient Distribution) program supports direct federal allocation of COVID-19 outpatient therapeutics, such as casirivimab/imdevimab and bamlanivimab to facilities that have the staffing, supplies, and means to administer mAb infusion.

SPEED is separate yet complementary to the state-based therapeutic allocation system to support distribution of therapeutic products to long-term care facilities, dialysis centers, federally qualified health centers, and correctional facilities.

 

mAb icon

Casirivimab/imdevimab

To quickly get casirivimab/imedvimab into the hands of health care providers, HHS is coordinating with the therapeutics’ manufacturer and distributor and state, territorial and national health departments, and medical organizations and associations. Allocation of casirivimab/imdevimab by jurisdiction is updated weekly.

 

mAb icon

Bamlanivimab

HHS is quickly getting bamlanivimab into the hands of health care providers by coordinating with the therapeutics’ manufacturer and distributor and state, territorial and national health departments, and medical organizations and associations. Allocation of bamlanivimab by jurisdiction is updated weekly.



  • This page last reviewed: February 17, 2021